{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Monotherapy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Combination Therapy (receiving AVD or NAVD)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization. Toxicities were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.","groups":[{"description":"Four doses of nivolumab flat dose 240 mg IV were administered every 2 weeks (monotherapy phase), followed by 12 doses of the combination of AVD (adriamycin/ doxorubicin 25 mg/m2, vinblastine 6 mg/m2, dacarbazine 375 mg/m2) chemotherapy and nivolumab flat dose 240 mg IV for 6 cycles (combination phase).","id":"OG000","title":"Cohort D: Newly Diagnosed, Previously Untreated Advanced Stage cHL (Stage IIB, III and IV)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants in Cohort D","reportingStatus":"POSTED","timeFrame":"From first dose of the considered therapy phase to 30 days after last dose of study therapy phase (or up to first dose of combination if any when considering the monotherapy period) (an average of 8 months and a maximum of 11 months)","title":"Number of Participants With Serious Adverse Events (SAEs) in Cohort D","type":"SECONDARY","unitOfMeasure":"Participants"}